Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors, or gliflozins, lower blood glucose levels by preventing the reabsorption of glucose in the kidney. Sodium Glucose Co-Transporter-2 are proteins that occur in the kidneys (and to some extent brain, liver, and intestine) and play an important role in balancing the blood glucose. SGLT2 is the major transport protein and promotes reabsorption from the glomerular filtration back into circulation. It is responsible for approximately 90% of the kidney’s glucose reabsorption.
SGLT2 inhibitors have also been shown to have a positive cardiovascular effect for those individuals who have type 2 diabetes.